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The development of new drugs is a highly complex and expensive process, so it is crucial that 
less promising compounds are rejected early in the discovery phase before progressing to 
more expensive phases. This scenario impels researchers to refine and speed up the drug 
discovery process and to seek tools to support decisions related to modifications of the drug 
chemical structure to improve drugs’ properties and thus increase the probability of success in 
the process of drug discovery. [1], [2] In the drug discovery process it should be considered 
that in physiological environment there will be reciprocal interactions between drugs and 
biological interfaces, such as cell membranes or plasma proteins, and from those interactions 
different pharmacokinetic profiles can be achieved. [3]  Thus, it is important to develop in 
vitro high throughput methods to evaluate the pharmaceutical profile, consisting in measuring 
properties such as permeability, lipophilicity, plasma protein binding, and biophysical 
changes of the membranes, which in turn affect other properties, such as the bioavailability of 
a drug and its pharmacokinetic profile. [4] Herein, the characterization of a newly synthesized 
drug (MIT-3) will be based on the measurement of fundamental biophysical properties, which 
allow inferring about its ADMET profile (absorption, distribution, excretion and toxicity at 
the membrane level). For this purpose, lipid-based colloidal nanosystems of different 
compositions were prepared as membrane mimetic models and several biophysical techniques 
were applied: derivative spectroscopy; quenching of steady-state and time-resolved 
fluorescence; quenching of intrinsic fluorescence of human serum albumin; synchronous 
fluorescence; dynamic and electrophoretic light scattering, differential scanning calorimetry 
and small and wide angle x-ray diffraction. The application of these techniques allowed to 
predict that MIT-3 has an ubiquitous location at the membrane level, presenting good 
membrane permeability and a good distribution in the therapeutic target. However, it is also 
predicted bioaccumulation with distribution in non-therapeutic targets and under conditions of 
prolonged exposure the drug may cause membrane toxicity as concluded by the impairment 
of membrane biophysical properties. It is also possible to conclude that the biophysical 
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techniques and the biomimetic models used, constitute a toolbox of strategies for the future 
evaluation of other drugs.   
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